As #VisitingResearchFellow, I am deeply grateful for the support and the example of the greatest mentor @DrDavidLarson ! Truly #CRS @MayoClinicSurg is a extraordinary environment of brilliant and careful surgeons governed by practice, #education and #research @MayoMrfa

Great! 🚽📱😩💩 Like we needed 1 more cause for hemorrhoids. 37% of smartphone users spending > 5 mins/visit on the toilet, compared to 7% of non-smartphone users (p=0.006). Smartphone use on the toilet associated with 46% ⬆️risk of hemorrhoids (p=0.044) https://t.co/LJFKzBx2Qe

@Carste92 @alice_gori @ClaudioIsopi @DFerrariMD @DrEmanueleRausa @GianlucaPellino @AntoninoSpin #ColorectalSurgery #RectalCancer #TME #SurgicalOncology #NeoadjuvantTherapy #NAT #EvidenceBasedMedicine #CollaborativeResearch #SoMe #SoMe4Surgery #SurgEd #Education #SurgicalResearch #AnswerYourQuestions

Thanks to the COVID-CRC Collaborative Group 🇮🇹and to the authors @ MatteoRottoli @Carste92 @alice_gori @ClaudioIsopi @DFerrariMD @DrEmanueleRausa @GianlucaPellino @AntoninoSpin and all the authors

What should change: - No RCT explored pCR and surgical outcomes with a timing >12 weeks! An exception (almost) is the ongoing RCT TiMiSNAR comparing 8w and 12w (min) https://t.co/4kOzn4ugWR @IgorMonsellato Our TIMING study justify the equipoise of a >12w timeframe after SCRT !!

What was new: - >12 w between SCRT and surgery showed significantly improved pCR rates (OR 4.99 !!!) with similar surgical outcomes.

We found out that: - Delaying surgery (>12weeks) did not increase surgical complications after NAT differing from the recently published CRONOS Study (10.1001/jamasurg.2023.2521) - An optimal time to surgery after nCRT was not associated with pCR or any surgical outcomes.

We compared time from Neoadjuvant therapy (NAT) to surgery stratified for - timing (<8w; 8-12w; >12w) - different NAT protocols: Chemoradiotherapy (nCRT), Short-course radiotherapy only (SCRT) Long-course radiotherapy only (LCRT) and Total Neoadjuvant Therapy (TNT)

This new study explores the optimal timing of rectal cancer resection after neoadjuvant therapy (NAT) to maximize oncological benefits while minimizing perioperative risks. Data comes from the largest national cohort for colorectal cancer in Italy (81 centers; >18000 pts).

🚨🚨🚨 New study alert "Rectal cancer surgery TIMING after neoadjuvant therapy: balancing downstaging and perioperative outcomes" just published in Surgical Oncology https://t.co/uBlKzgxJqC

Did you know...#escp25 👉It's the 20th birthday of ESCP 🎉🥳🎂 👉The first Tripartite meeting was in 1969 👉It's called Tripartite but it's now an alliance of 6 Societies! 👉We are having a Global impact together 🌍 👉Collaboration is improving quality, education & #research

To my friends and amazing research fellows. Thank you for sharing your brilliant minds with me. I am grateful and proud of all your accomplishments ⁦@escp_tweets⁩ #tripartite ⁦@MayoClinic⁩

⏳ Have you filled out the GRIFF Collaborative survey yet? We’re building global consensus on intestinal failure & fistula care—and your input is key. 📝 It only takes 4 minutes: https://t.co/3RPHYaO4iu 🔁 RT to help us reach more voices! #GRIFFcollab #ECF #MedTwitter

#INTESTINE study results are out https://t.co/RKrOtPk4BX

🚨 New data on #temporarystomas in #Crohnsdisease: 🔹 Reversal @ 6mo: 30.2% 🔹 Reversal @ 18mo: 56.9% 🔹 Non-reversal: med therapy (39%), unfit (17%), patient's choice (20%) 🔹 Stoma morbidity: 29.4% "Temporary" often isn’t. #IBDsurgery @BjsOpen @GCalini @ZGaroufalia @SWexner

Exciting news! Our article on abdominal drains in emergency colorectal surgery received enough views to be a Top Viewed Article. Read it here https://t.co/hPaTTmGWN1 #TopViewedArticle @wileyinresearch @ColorectalDis @YouESCP @escp

Do you agree or not? @ASCRS_1 @ACPGBI @SAGES_Updates LASER Focus on Long-Term Outcomes for Diverticular Disease

Here we go again!? #diverticulitis #rct Sigmoid Resection vs Conservative Treatment After Diverticulitis

Interesting new Finnish RCT in @JAMASurgery evaluating ICG's impact on anastomotic leak in colon surgery. The results won't make you switch camps, regardless of which one you're in, but they're important: -No difference in AL rates, reoperations, or overall complications between

Congrats to @JyiChengNg (a rising resident in GS at Hopkins!) for helping to define a significant improvement to prognostics in #Rectal #Cancer. https://t.co/GNvaJUvBN2 @MayoClinic @MayoCancerCare

Just out https://t.co/TTXTNZ6VCi Endoscopic Recurrence Reduced after Extended Mesenteric Resection Multicentre, Randomised Control Trial (6, 12 and 18 months post true Extended Mesenteric Resection) @AGA_Gastro @NatRevGastroHep @NEJM @NatureMedicine @LancetGastroHep